LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel ; Online: Correspondence to: "Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors".

    Dobiasova, Milada

    Atherosclerosis

    2021  Band 335, Seite(n) 148

    Mesh-Begriff(e) Atherosclerosis/diagnosis ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/epidemiology ; Humans ; Risk Factors
    Sprache Englisch
    Erscheinungsdatum 2021-09-04
    Erscheinungsland Ireland
    Dokumenttyp Letter ; Comment
    ZDB-ID 80061-2
    ISSN 1879-1484 ; 0021-9150
    ISSN (online) 1879-1484
    ISSN 0021-9150
    DOI 10.1016/j.atherosclerosis.2021.09.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 226: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.

    Dobiásová, Milada

    Clinical chemistry

    2004  Band 50, Heft 7, Seite(n) 1113–1115

    Mesh-Begriff(e) Cholesterol, HDL/blood ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin Resistance ; Pioglitazone ; Plasma ; Randomized Controlled Trials as Topic ; Thiazolidinediones/therapeutic use ; Triglycerides/blood
    Chemische Substanzen Cholesterol, HDL ; Hypoglycemic Agents ; Thiazolidinediones ; Triglycerides ; Pioglitazone (X4OV71U42S)
    Sprache Englisch
    Erscheinungsdatum 2004-06-24
    Erscheinungsland England
    Dokumenttyp Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1373/clinchem.2004.033175
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.171: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography.

    Frohlich, Jiri / Dobiásová, Milada

    Clinical chemistry

    2003  Band 49, Heft 11, Seite(n) 1873–1880

    Abstract: Background: We examined the predictive value of various clinical and biochemical markers for angiographically defined coronary artery disease (aCAD). Specifically, we assessed the value of the ratio of plasma triglyceride (TGs) to HDL-cholesterol (HDL-C) ...

    Abstract Background: We examined the predictive value of various clinical and biochemical markers for angiographically defined coronary artery disease (aCAD). Specifically, we assessed the value of the ratio of plasma triglyceride (TGs) to HDL-cholesterol (HDL-C) and the fractional esterification rate of cholesterol in plasma depleted of apolipoprotein B (apoB)-containing lipoproteins (FER(HDL)), a functional marker of HDL and LDL particle size.
    Methods: Patients (788 men and 320 women) undergoing coronary angiography were classified into groups with positive [aCAD(+)] and negative [aCAD(-)] findings. Patient age, body mass index, waist circumference, blood pressure (BP), medications, drinking, smoking, exercise habits, and plasma total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-unesterified cholesterol, HDL-C, TGs, FER(HDL), apoB, log(TG/HDL-C), and TC/HDL-C were assessed. Lipids and apoproteins were measured by standard laboratory procedures; FER(HDL) was determined by a radioassay.
    Results: Members of the aCAD(+) group were older and had a higher incidence of smoking and diabetes than those in the aCAD(-) group. The aCAD(+) group also had higher TG, apoB, FER(HDL), and log(TG/HDL-C) and lower HDL-C values. aCAD(+) women had greater waist circumference and higher plasma TC and TC/HDL-C. aCAD(+) men, but not women, had higher plasma LDL-C. In the multivariate logistic model, the significant predictors of the presence of aCAD(+) were FER(HDL), age, smoking, and diabetes. If only laboratory tests were included in the multivariate logistic model, FER(HDL) appeared as the sole predictor of aCAD(+). Log(TG/HDL-C) was an independent predictor when FER(HDL) was omitted from multivariate analysis.
    Conclusions: FER(HDL) was the best laboratory predictor of the presence of coronary atherosclerotic lesions.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers/blood ; Cholesterol/blood ; Cholesterol/metabolism ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Coronary Angiography ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/diagnostic imaging ; Esterification ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Predictive Value of Tests ; Regression Analysis ; Triglycerides/blood
    Chemische Substanzen Biomarkers ; Cholesterol, HDL ; Cholesterol, LDL ; Triglycerides ; Cholesterol (97C5T2UQ7J)
    Sprache Englisch
    Erscheinungsdatum 2003-10-24
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1373/clinchem.2003.022558
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.171: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography

    Dobiášová, Milada / Frohlich, Jiri / Šedová, Michaela / Cheung, Marian C / Brown, B. Greg

    Journal of lipid research JLR. 2011 Mar., v. 52, no. 3

    2011  

    Abstract: We examined the association between rate of cholesterol esterification in plasma depleted of apolipoprotein B-containing lipoproteins (FERHDL), atherogenic index of plasma (AIP) [(log (TG/HDL-C)], concentrations, and size of lipoproteins and changes in ... ...

    Abstract We examined the association between rate of cholesterol esterification in plasma depleted of apolipoprotein B-containing lipoproteins (FERHDL), atherogenic index of plasma (AIP) [(log (TG/HDL-C)], concentrations, and size of lipoproteins and changes in coronary artery stenosis in participants in the HDL-Atherosclerosis Treatment Study. A total of 160 patients was treated with simvastatin (S), niacin (N), antioxidants (A) and placebo (P) in four regimens. FERHDL was measured using a radioassay; the size and concentration of lipoprotein subclasses were determined by nuclear magnetic resonance spectroscopy. The S+N and S+N+A therapy decreased AIP and FERHDL, reduced total VLDL (mostly the large and medium size particles), decreased total LDL particles (mostly the small size), and increased total HDL particles (mostly the large size). FERHDL and AIP correlated negatively with particle sizes of HDL and LDL, positively with VLDL particle size, and closely with each other (r = 0.729). Changes in the proportions of small and large lipoprotein particles, which were reflected by FERHDL and AIP, corresponded with findings on coronary angiography. Logistic regression analysis of the changes in the coronary stenosis showed that probability of progression was best explained by FERHDL (P = 0.005). FERHDL and AIP reflect the actual composition of the lipoprotein spectrum and thus predict both the cardiovascular risk and effectiveness of therapy. AIP is already available for use in clinical practice as it can be readily calculated from the routine lipid profile.
    Sprache Englisch
    Erscheinungsverlauf 2011-03
    Umfang p. 566-571.
    Erscheinungsort American Society for Biochemistry and Molecular Biology
    Dokumenttyp Artikel
    ZDB-ID 80154-9
    ISSN 1539-7262 ; 0022-2275
    ISSN (online) 1539-7262
    ISSN 0022-2275
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 175: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.

    Dobiásová, Milada / Frohlich, Jiri / Sedová, Michaela / Cheung, Marian C / Brown, B Greg

    Journal of lipid research

    2011  Band 52, Heft 3, Seite(n) 566–571

    Abstract: We examined the association between rate of cholesterol esterification in plasma depleted of apolipoprotein B-containing lipoproteins (FER(HDL)), atherogenic index of plasma (AIP) [(log (TG/HDL-C)], concentrations, and size of lipoproteins and changes in ...

    Abstract We examined the association between rate of cholesterol esterification in plasma depleted of apolipoprotein B-containing lipoproteins (FER(HDL)), atherogenic index of plasma (AIP) [(log (TG/HDL-C)], concentrations, and size of lipoproteins and changes in coronary artery stenosis in participants in the HDL-Atherosclerosis Treatment Study. A total of 160 patients was treated with simvastatin (S), niacin (N), antioxidants (A) and placebo (P) in four regimens. FER(HDL) was measured using a radioassay; the size and concentration of lipoprotein subclasses were determined by nuclear magnetic resonance spectroscopy. The S+N and S+N+A therapy decreased AIP and FER(HDL), reduced total VLDL (mostly the large and medium size particles), decreased total LDL particles (mostly the small size), and increased total HDL particles (mostly the large size). FER(HDL) and AIP correlated negatively with particle sizes of HDL and LDL, positively with VLDL particle size, and closely with each other (r = 0.729). Changes in the proportions of small and large lipoprotein particles, which were reflected by FER(HDL) and AIP, corresponded with findings on coronary angiography. Logistic regression analysis of the changes in the coronary stenosis showed that probability of progression was best explained by FER(HDL) (P = 0.005). FER(HDL) and AIP reflect the actual composition of the lipoprotein spectrum and thus predict both the cardiovascular risk and effectiveness of therapy. AIP is already available for use in clinical practice as it can be readily calculated from the routine lipid profile.
    Mesh-Begriff(e) Antioxidants/therapeutic use ; Apolipoproteins B/metabolism ; Atherosclerosis/blood ; Atherosclerosis/diagnostic imaging ; Atherosclerosis/drug therapy ; Atherosclerosis/metabolism ; Cholesterol/blood ; Cholesterol/metabolism ; Coronary Angiography ; Coronary Stenosis/complications ; Coronary Stenosis/drug therapy ; Drug Combinations ; Esterification ; Humans ; Lipoproteins/blood ; Lipoproteins/chemistry ; Niacin/therapeutic use ; Particle Size ; Simvastatin/therapeutic use
    Chemische Substanzen Antioxidants ; Apolipoproteins B ; Drug Combinations ; Lipoproteins ; Niacin (2679MF687A) ; Cholesterol (97C5T2UQ7J) ; Simvastatin (AGG2FN16EV)
    Sprache Englisch
    Erscheinungsdatum 2011-01-11
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80154-9
    ISSN 1539-7262 ; 0022-2275
    ISSN (online) 1539-7262
    ISSN 0022-2275
    DOI 10.1194/jlr.P011668
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 175: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Buch: Úloha lecithin-cholesterol acyltransferasy (LCAT) v metabolismu cholesterolu

    Dobiásová, Milada

    (Studie CSAV ; 3, 85)

    1985  

    Verfasserangabe Milada Dobiásová
    Serientitel Studie CSAV ; 3, 85
    Mesh-Begriff(e) Cardiovascular Diseases/etiology ; Cholesterol, Dietary/adverse effects
    Sprache Tschechisch
    Umfang 105 p. :, ill.
    Ausgabenhinweis Vyd. 1.
    Verlag Academia
    Erscheinungsort Praha
    Dokumenttyp Buch
    Datenquelle Katalog der US National Library of Medicine (NLM)

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  7. Artikel: Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.

    Vrablík, Michal / Dobiásová, Milada / Stulc, Tomás / Kasalová, Zdislava / Dolezalová, Radka / Prázný, Martin / Fait, Tomas / Ceska, Richard

    Neuro endocrinology letters

    2008  Band 29, Heft 1, Seite(n) 146–150

    Abstract: Background: Particle size distribution in both HDL and LDL is reflected in the fractional esterification rate of cholesterol by lecithin cholesterol acyltransferase (LCAT) in plasma depleted of apoB containing lipoproteins (FER(HDL)). We studied FER(HDL) ...

    Abstract Background: Particle size distribution in both HDL and LDL is reflected in the fractional esterification rate of cholesterol by lecithin cholesterol acyltransferase (LCAT) in plasma depleted of apoB containing lipoproteins (FER(HDL)). We studied FER(HDL) in a group of patients with type 2 diabetes and determined the impact of two different PPAR agonists (fenofibrate and rosiglitazone) on this marker of lipoprotein particle quality.
    Patients and methods: 66 patients with type 2 diabetes (26 women) and 32 control subjects (19 women) were included in the study. 33 patients received fenofibrate and 33 rosiglitazone as add on therapy. Average duration of treatment was 4 months. Plasma lipoprotein glucose levels were determined using an automated analyzer (COBAS Mira, Roche). LDL cholesterol concentrations were calculated by Friedewald formula. FER(HDL) was determined by a radioassay after precipitating apo-B containing particles of plasma. The assays were performed at baseline and at the end of each treatment. SPSS base program was used for statistical evaluation.
    Results: Both fenofibrate and rosiglitazone resulted in a significant decrease of FER(HDL) (24.62 +/- 11.27%/h vs. 19.93 +/- 10.34%/h; 20.0 +/- 6.1%/h vs. 15.8 +/- 5.8%/h, p < 0.001). Rosiglitazone was significantly more effective in FER(HDL) lowering than fenofibrate (p < 0,02)
    Conclusions: Both fenofibrate and rosiglitazone improve FER(HDL) in patients with type 2 diabetes. The effect is more pronounced for rosiglitazone. Qualitative change of plasma lipoproteins reflected by FER(HDL) can contribute to antiatherogenic action of PPAR agonists. On contrary, changes of lipoprotein composition induced by PPAR agonists cannot explain adverse cardiovascular effects observed in some large clinical trials with PPAR agonists.
    Mesh-Begriff(e) Aged ; Biomarkers/blood ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Cholesterol, LDL/blood ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Fenofibrate/adverse effects ; Fenofibrate/pharmacology ; Fenofibrate/therapeutic use ; Humans ; Lipoproteins/blood ; Male ; Middle Aged ; Peroxisome Proliferator-Activated Receptors/agonists ; Phosphatidylcholine-Sterol O-Acyltransferase/blood ; Predictive Value of Tests ; Risk Factors ; Thiazolidinediones/adverse effects ; Thiazolidinediones/pharmacology ; Thiazolidinediones/therapeutic use
    Chemische Substanzen Biomarkers ; Cholesterol, LDL ; Lipoproteins ; Peroxisome Proliferator-Activated Receptors ; Thiazolidinediones ; rosiglitazone (05V02F2KDG) ; Phosphatidylcholine-Sterol O-Acyltransferase (EC 2.3.1.43) ; Fenofibrate (U202363UOS)
    Sprache Englisch
    Erscheinungsdatum 2008-02
    Erscheinungsland Sweden
    Dokumenttyp Controlled Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 135951-4
    ISSN 0172-780X
    ISSN 0172-780X
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 2384: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang